Itch is the most burdensome symptom for some patients with eczema—but you already know that.
VTAMA cream may help rapidly reduce itch. Itch relief as early as Day 2 was reported in the pivotal studies by some patients.
Patients using VTAMA cream had meaningful improvement in itch at the end of just 1 week compared to patients using cream with no active ingredient.
For some patients on VTAMA cream, itch relief continued to improve over the 8-week clinical study.
*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.
Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:
Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis), headache, itching (pruritus), and flu (influenza).
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, red raised bumps around the hair pores (folliculitis), lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please read the Prescribing and Patient Information for VTAMA cream and discuss it with your doctor.
Back to top
